Mr. Speaker, as I mentioned, this is a quasi-judicial agency and should it find that the price of patented medicines sold in Canada is excessive, it has the power to roll back the price to the non-excessive level and to collect any excess revenue that may have occurred.
That is the process and we will follow that process.